Literature DB >> 10640548

In vitro infection of cells of the monocytic/macrophage lineage with bovine leukaemia virus.

A Doménech1, J Goyache, L Llames, M Jesús Payá, G Suárez, E Gómez-Lucía.   

Abstract

The oncogenic retrovirus bovine leukaemia virus (BLV) primarily infects B cells. Most infected animals remain asymptomatic for long periods of time before an increase in circulating B cells or localized tumours can be observed. This long clinical latency period may be explained by cells of the monocyte/macrophage lineage (M/M) becoming infected and acting as a reservoir for the virus, as shown for other retroviruses (human immunodeficiency virus-1, feline immunodeficiency virus). M/M cells in different stages of differentiation (HL-60, THP-1, U-937, J774, BGM, PM2, primary macrophages of sheep and cows) were cultured with BLV produced by permanently infected donor cells (FLKBLV and BLV-bat(2)). Donor cells were inhibited from multiplying by either irradiation or treatment with mitomycin C. In other experiments, supernatant from donor cells containing virus was used. In co-culture with the donor cells, the less differentiated monocytic cells showed severe cellular changes such as differentiation, vacuolization, cell lysis and membrane blebbing; apoptosis was a frequent phenomenon. Budding and extracellular viruses were also observed. The more differentiated macrophage cells, although they showed less signs of infection by microscopy, had a complete BLV protein profile, as seen by Western blotting; bands corresponding to p24CA (Gag) and its precursors were clearly seen. In addition, gp51SU was identified by syncytia formation assays. It is concluded that M/M cells may be infected by BLV, the consequences of the infection differing according to the type of cell.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10640548     DOI: 10.1099/0022-1317-81-1-109

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

1.  Ultrastructural studies on dengue virus type 2 infection of cultured human monocytes.

Authors:  Jesus A Mosquera; Juan Pablo Hernandez; Nereida Valero; Luz Marina Espina; German J Añez
Journal:  Virol J       Date:  2005-03-31       Impact factor: 4.099

Review 2.  Cytoplasmic vacuolization in cell death and survival.

Authors:  Andrey V Shubin; Ilya V Demidyuk; Alexey A Komissarov; Lola M Rafieva; Sergey V Kostrov
Journal:  Oncotarget       Date:  2016-08-23

3.  Overexpression of bovine leukemia virus receptor SLC7A1/CAT1 enhances cellular susceptibility to BLV infection on luminescence syncytium induction assay (LuSIA).

Authors:  Hirotaka Sato; Lanlan Bai; Liushiqi Borjigin; Yoko Aida
Journal:  Virol J       Date:  2020-04-22       Impact factor: 4.099

4.  In vitro Susceptibility of Human Cell Lines Infection by Bovine Leukemia Virus.

Authors:  Nury N Olaya-Galán; Skyler Blume; Kan Tong; HuaMin Shen; Maria F Gutierrez; Gertrude C Buehring
Journal:  Front Microbiol       Date:  2022-03-14       Impact factor: 5.640

5.  Milk Macrophage Function in Bovine Leukemia Virus-Infected Dairy Cows.

Authors:  Ewerton de Souza Lima; Maiara Garcia Blagitz; Camila Freitas Batista; Alexandre José Alves; Artur Cezar de Carvalho Fernandes; Eduardo Milton Ramos Sanchez; Hugo Frias Torres; Soraia Araújo Diniz; Marcos Xavier Silva; Alice Maria Melville Paiva Della Libera; Fernando Nogueira de Souza
Journal:  Front Vet Sci       Date:  2021-06-17

Review 6.  Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human.

Authors:  Nicolas Gillet; Arnaud Florins; Mathieu Boxus; Catherine Burteau; Annamaria Nigro; Fabian Vandermeers; Hervé Balon; Amel-Baya Bouzar; Julien Defoiche; Arsène Burny; Michal Reichert; Richard Kettmann; Luc Willems
Journal:  Retrovirology       Date:  2007-03-16       Impact factor: 4.602

7.  Comment on 'The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study'.

Authors:  Bernard Friedenson
Journal:  Br J Cancer       Date:  2016-07-26       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.